期刊文献+

比较6种氟喹诺酮类药物对金黄色葡萄球菌的防耐药变异浓度 被引量:3

Comparison the mutant prevention concentration of 6 kinds of fluoroquinolones for Staphylococcus aureus
下载PDF
导出
摘要 目的比较6种氟喹诺酮类药物对临床分离金黄色葡萄球菌耐药突变体的选择能力。方法用呼吸道标本,选择对苯唑西林、环丙沙星敏感的金黄色葡萄球菌36株,采用标准琼脂二倍稀释法、标准琼脂平板稀释法,测定6种氟喹诺酮类药物对金黄色葡萄球菌的MIC、MPC。结果 MPC值比较,莫西沙星最低;而环丙沙星最高。选择指数(MPC90/MIC90)较低有如下4种:莫西沙星、卡屈沙星、加替沙星和帕珠沙星,均为2。6种药物MPC90值与其体内药动学参数比较,莫西沙星和卡屈沙星小于其Cmax。结论莫西沙星、卡屈沙星和加替沙星对金葡菌的MPC值较低,突变选择窗范围相对较窄。 Objective To determine the mutant prevention concentration(MPC) of 6 kinds of fluoroquinolones for the clinical isolated Staphylococcus aureus,and to compare the capacity of the choosing on the resistant mutant strain of the 6 kinds of fluoroquinolones.Methods The minimal inhibitory concentrations(MIC) and MPC of ciprofloxacin,levofloxacin,gatifloxacin,caderofloxacin,mixifloxacin and pazufloxacin were determined on 36 strains of S.aureus isolated from clinic which were sensitive to oxacillin and ciprofloxacin by agar two-fold dilution method and ager plates dilution method.Results For MPC,mixifloxacin was the lowest,then caderofloxacin,gatifloxacin,pazufloxacin and levofloxacin,and ciprofloxacin was the highest among the 6 kinds of fluoroquinolones against Staphylococcus aureus.As for MIC90/MPC90,mixifloxacin,caderofloxacin,gatifloxacin and pazufloxacin were more lower,levofloxacin and ciprofloxacin were more higher.The comparison of the pharmacokinetic parameters in vivo to MPC90 for the 6 kinds of fluoroquinolones against the 36 strains of S.aureus showed that MPC90 was less than Cmaxfor moxifloxacin and caderofloxacin.Conclusion Moxifloxacin,caderofloxacin and gatifloxacin have the lower MPC and narrower mutant selective window with a high ability to restrict the selection of S.aureus resistant mutants among the 6 kinds of fluoroquinolones against the S.aureus.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2011年第9期676-678,共3页 The Chinese Journal of Clinical Pharmacology
关键词 防耐药变异浓度 氟喹诺酮 金黄色葡萄球菌 mutant prevention concentration fluoroquinolones Staphylococcus aureus
  • 相关文献

参考文献5

二级参考文献59

共引文献359

同被引文献43

  • 1陈雪华,何礼贤.氟喹诺酮类药物的药动学和药效学[J].中华医学信息导报,2004(10):20-20. 被引量:8
  • 2孙晶.喹诺酮类药物的临床应用及不良反应[J].黑龙江医学,2004,28(5):379-380. 被引量:1
  • 3崔俊昌,刘又宁,王睿,梁蓓蓓,郑专杰.氟喹诺酮类药物对临床分离金黄色葡萄球菌的防耐药变异浓度[J].中华医院感染学杂志,2005,15(6):611-614. 被引量:10
  • 4Fish DN,Chow AT.The clinical pharmacikinetics of levofloxacin[J].Clin Pharmacokinet,1997,32(2):101-119.
  • 5Zhanel GG,Ennis K,Vercaigne L,et al.A critical review of the fluoroquinolones:focus on respiratory tract infections[J].Drugs,2002,62(1):13-59.
  • 6Crandon JL,Kuti JL,Jones RN,et al.Comparison of2002-2006 OPTAMA programs for US hospitals:focus on gram-negative resistance[J].Ann Pharmacother,2009,43(2):220-227.
  • 7Mavroidi A,Miriaqou V,Liakopoulos A,et al.Ciprofloxacin-resistant escherichia coli in central Greece:mechanisms of resistance and molecular identification[J].BMC Infect Dis,2012,12(1):371.
  • 8Hassan WM,Hashim A,Domany R.Plasmid mediated quinolone resistance determinants qnr aac(6')-lb-cr,and qepin ESBL-producing escherichia coli clinical isolates form Egypt[J].India J Med Microbiol,2012,30(4):442-447.
  • 9Kontou P,Chatzika K,Pitsiou G,et al.Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease[J].Antimicrob Agents Chemother,2011,55(9):4149-4153.
  • 10Garrelts JC,Jost G,Kowalsky GF,et al.Ciprofloxacin pharmacokinetics in burn patients[J].Antimicrob Agents Chemother,1996,40(5):1153-1156.

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部